The U.S. Food and Drug Administration (FDA) launched the Expedited Investigational New Drug (IND) Pilot Program on 15th September, 2026, initiated under the HHS Operation Trialblazer
CDSCO suspended HCG-Bangalore's Ethics Committee for 24 months after finding nine unreported adverse events, including three deaths. Here's what it means for clinical trial patients in India.